Background: Treatments for autoimmune blistering disease carry significant risks of medical complications and can affect the patient's quality of life. Recently, the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire was developed in Australia. Objective: The objective of this study was to evaluate the reliability and validity of the Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire in Chinese patients with autoimmune blistering diseases. Methods: The Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire was produced by forward-backward translation and cross-cultural adaptation of the original English version. Autoimmune blistering disease patients recruited in the study self-administered the Chinese Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, the Dermatology Life Quality Index and the 36-item Short-Form Health Survey. Reliability of the Chinese Treatment of Autoimmune Bullous Disease Quality of Life was evaluated using internal consistency and test-retest (days 0 and 7) methods. Validity was analyzed by face, content, construct, convergent and discriminant validity measures.
Introduction
Autoimmune blistering disease is a group of uncommon skin and mucosal diseases that can significantly affect the patients' quality of life. 1 The diseases have variable clinical manifestations and include pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, paraneoplastic pemphigus, linear immunoglobulin A bullous disease and pemphigoid gestationis. In the past, these diseases carried a guarded prognosis with secondary infection of bullae culminating in sepsis. However with the advent of immunosuppressive therapies, autoimmune blistering diseases tend to be chronic conditions with a significant morbidity. 2 Treatments for autoimmune blistering disease carry significant risks of medical complications and can affect the patient's quality of life. Furthermore, it may be difficult to differentiate treatment-related effects on the quality of life from the disease burden or the adverse effects of the treatments themselves. 3 The lack of uniform and validated outcome measures hampers progress in evaluating treatment impact on patients with autoimmune blistering disease. Standardization of such measures is pivotal to accurately monitor the patient and to pool results from randomized controlled trials for meta-analysis which will provide better understanding of the optimal autoimmune blistering disease therapies. 1 Recently, the scholars of Australia published the Treatment of Autoimmune Bullous Disease Quality of Life and the Autoimmune Bullous Disease Quality of Life questionnaires using standardized methodology in autoimmune blistering disease patients. 3, 4 The Treatment of Autoimmune Bullous Disease Quality of Life questionnaire was the first validated quality of life tool specific to the adverse effects of treatments in autoimmune blistering disease patients and has been shown to be a reliable and valid instrument to measure treatment burden. 3 In this study, we aimed to validate the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire in Chinese patients with autoimmune blistering disease with a view to using it as an outcome measure for treatment evaluation and as an end point in future clinical trials in Chinese autoimmune blistering disease patients.
Methods

Study questionnaire
As a self-administered questionnaire, the formal Treatment of Autoimmune Bullous Disease Quality of Life questionnaire of Chinese version was produced with forward-backward translation, cross-cultural adaptation, pilot questionnaire, review of bullous disease experts and adjusting the arrangement using standard method. Prior to the study, the approval of the Ethics Committee of the Shandong Provincial Hospital for Skin Diseases was obtained.
Patient recruitment
All the patients were from Shandong Provincial Hospital for Skin Diseases. Inclusion criteria were over 18 years of age, a confirmed histopathological and immunohistological diagnosis of autoimmune blistering disease and sufficient education to complete the questionnaire. General patient characteristics were recorded including disease stage, gender, concomitant and past medications and for the pemphigus vulgaris patients the indirect immunofluorescence titers around the time of the survey. As previously recommended, we selected five times the number of items as the minimum necessary sample size. 5 There are 17 items in the questionnaire. Hence, we aimed to recruit at least 85 patients with autoimmune blistering disease.
All the patients recruited in the study were asked to complete the Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, the Dermatology Life Quality Index 6 and the 36-item Short-Form Health Survey 7 without assistance. The outpatients performed the surveys after their clinical appointments in the clinic on day 0 and they were also asked to take home a stamped addressed envelope containing the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire to complete on day 7 and return it to the investigator. The inpatients completed the questionnaires on days 0 and 7 while in the ward.
Statistical analysis
All statistical analyses were performed using SPSS 10.01 software (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
Reliability
Internal consistency was measured using Cronbach's alpha coefficient which also tested for construct validity. 8 Test-retest reliability was assessed by comparing the responses of a subset of patients who completed the questionnaire on both days 0 and 7. The intraclass correlation coefficient was calculated to determine the ability of the tool to give concordant results at different times.
Validity
Validation methods included assessment of face, content, construct, convergent and discriminant validities. 3 Face and content validities were established by forward-backward translation of the Treatment of Autoimmune Bullous Disease Quality of Life and by review of the questionnaire by the panel of bullous disease experts. Convergent validity was determined by calculating Spearman's correlation coefficients for the Treatment of Autoimmune Bullous Disease Quality of Life and Dermatology Life Quality Index or the Treatment of Autoimmune Bullous Disease Quality of Life and 36-item Short-Form Health Survey. Discriminant validity was evaluated by comparing the questionnaire scores of (i) outpatients and inpatients, (ii) patients on steroids and steroid-sparing medications, (iii) men and women, (iv) indirect immunofluorescence-positive and indirect immunofluorescence-negative patients with pemphigus vulgaris (all using Student's t-test) and (v) the three patient subtypes (pemphigus vulgaris, bullous pemphigoid and all others [pemphigus foliaceus, dermatitis herpetiformis, linear immunoglobulin A bullous disease, paraneoplastic pemphigus, epidermolysis bullosa acquisita and pemphigoid gestationis]) using one-way analysis of variance.
Factor analysis
Construct validity was also assessed through factor analysis. Exploratory factor analysis and principal component analysis followed by Oblimin rotation with Kaiser normalization were performed to assess the dimensionality of the 17 items and to validate the structure of the Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire. Significance was defined as a loading >0.4 or <−0.4. Item complexity occurred if an item loaded >0.4 or <−0.4 on more than one factor. If an item was complex and the difference in loading was at least 0.1, it was assigned to the factor on which it loaded more heavily. 3
Results
A total of 86 patients were recruited and completed the surveys between March 2015 and December 2015. All patients completed the day 0 questionnaire and 59 (68.6%) completed the day 7 questionnaire. None of the patients reported difficulties in understanding the questions.
Demographics
Patient demographics are presented in Table 1 . Of the 86 patients recruited, 56 (65.1%) were men and 30 (34.9%) were women. The patients' ages ranged from 18 to 77 years with a mean of 49.9 years. There were 72 outpatients and 14 inpatients. The number of school years completed ranged from 4 to 18 years with a mean of 9.3 years. Most of the patients had pemphigus vulgaris (n = 51), followed by bullous pemphigoid (n = 19), pemphigus foliaceus (n = 8), dermatitis herpetiformis (n = 3), linear immunoglobulin A bullous disease (n = 2), epidermolysis bullosa acquisita (n = 1), paraneoplastic pemphigus (n = 1) and pemphigoid gestationis (n = 1). The clinical disease stages were complete remission minimal therapy (n = 29), control of disease activity (n = 27), complete remission during tapering (n = 23), time to control of disease activity (n = 3), complete remission off therapy (n = 2), partial remission minimal therapy (n = 1) and relapse/flare (n = 1). 9 Concomitant and past medications included (in order of frequency) prednisone, methylprednisolone, cyclophosphamide, topical steroids, tetracycline, niacinamide, dapsone, azathioprine, cyclosporine, intravenous immunoglobulin and rituximab.
Patient scores
The Treatment of Autoimmune Bullous Disease Quality of Life total scores ranged from 1 to 47 out of a possible 51 points (original study; 0-45). The mean ± standard deviation scores were 17.43 ± 9.77 for all patients (original study; 16.3 ± 10.3), 17.22 ± 9.59 for pemphigus vulgaris, 17.74 ± 11.46 for bullous pemphigoid and 17.75 ± 8.73 for all other patients. The scores for the three disease subgroups are shown in Figure 1 . The item "dangerous medications" scored highest (2.05 ± 1.13), indicating the greatest impact on quality of life and the item "blood tests" scored lowest (0.49 ± 0.73). The scores for the individual items are shown in Table 2 . 
Reliability
The internal consistency and construct validity were acceptable with a Cronbach's alpha of 0.883 and this value was unaffected by Table 2 ]. The test-retest reliability of the questionnaire was also acceptable with a mean intraclass correlation coefficient value of 0.871 [ Figure 2 and Table 2 ].
Validity
With regard to convergent validity, the correlation coefficient for the Treatment of Autoimmune Bullous Disease Quality of Life and Dermatology Life Quality Index was 0.664 (P < 0.001) and for the Treatment of Autoimmune Bullous Disease Quality of Life and 36-item Short-Form Health Survey was -0.577 (P < 0.001). For pemphigus vulgaris patients, indirect immunofluorescence titers and Treatment of Autoimmune Bullous Disease Quality of Life scores showed a poor Spearman's rank correlation (r = 0.081, P = 0.572). Discriminant validity testing showed no significant differences in the Treatment of Autoimmune Bullous Disease Quality of Life scores of patients on steroids and steroid-sparing medication (t = 0.672, P = 0.503), outpatients and inpatients (t = 0.447, P = 0.656), indirect immunofluorescence-positive and indirect immunofluorescencenegative patients with pemphigus vulgaris (t = 1.270, P = 0.210) and men and women (t = 0.251, P = 0.802), all determined by Student's t-test. There was also no significant difference between the scores of the three patient subtypes (pemphigus vulgaris, bullous pemphigoid and others), as determined by one-way analysis of variance (F = 0.030, P = 0.971). Statistical analyses of validity and reliability measures are presented in Table 3 .
Factor analysis
Bartlett's test of sphericity (P < 0.001) and the Kaiser-Meyer-Olkin measure of sampling adequacy (0.818) suggested that factor analysis of the data was appropriate. 3 The Kaiser criterion suggested that five factors had eigenvalues >1, representing 66.8% of the cumulative variance of the 17 items. The Cattell scree plot suggested that three factors should be retained, representing 53.3% of the cumulative variance. The rotation matrix indicated that questions 2, 5, 6, 7, 12, 14, 15 and 16 were loaded on factor 1; questions 8, 9, 10, 11, 13 and 17 were loaded on factor 2 and questions 1, 3 and 4 were loaded on factor 3. The three dimensions represented are shown in Table 4 . Indian Journal of Dermatology, Venereology and Leprology | Volume 84 | Issue 4 | July-August 2018 The exploratory principal component analysis followed by Oblimin rotation with Kaiser normalization and the Catell scree plot suggested that three factors should be retained and the 17 items in the Chinese questionnaire must be distributed on three factors. However, in the original Treatment of Autoimmune Bullous Disease Quality of Life study, all items except item 1 loaded on factor 1, suggestive of a strong single-dimensional questionnaire. This discrepancy might be explained by the different patient cohorts, customs or cultures tested between the two studies.
There are several limitations to this study. First, this is a patientreported questionnaire and many patients were excluded because some patients were illiterate or could not finish the questionnaire by themselves. In a study of the 36-item Short-Form Health Survey in Morocco, the high illiteracy rate was overcome by having a single investigator administer the questionnaire to the patient. 13 The same approach could be taken in clinical practice when measuring the treatment burden in patients with autoimmune blistering disease. Second, the patients were recruited from a single hospital which might have resulted in some patient selection bias. Third, most of the recruited patients had relatively stable disease and the number with acute diseases was low. Further validation of the Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire would ideally involve more hospitals and include more extensive patient populations.
Conclusion
The Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire could be used to measure treatment burden and to serve as an end point in clinical trials in Chinese autoimmune blistering disease patients.
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